source
- Biogen CEO says company will pause new acquisitions and focus on developing existing pipelineBiogen's chief executive Christopher Viehbacher told analysts during the second-quarter earnings call that the company will slow its merger and acquisition activity for the foreseeable future. Aft…
- Vertex pays $28 million upfront to AbCellera for autoimmune T-cell engager collaborationVertex Pharmaceuticals has entered a collaboration with AbCellera, paying an upfront sum of $28 million to access the latter’s T-cell engager platform for autoimmune disease programs. Under the ag…